Meeting
2023 ASCO Annual Meeting
Multi-omic characterization of RCC1 expression and its association with molecular alterations, immune phenotypes, and cancer outcomes.
Authors
Brian Warnecke
University of California Irvine School of Medicine, Orange, CA
Brian Warnecke , Misako Nagasaka , Mohammed Najeeb Al Hallak , Sahar Bannoura , Chul Kim , Andrew Elliott , Balazs Halmos , Dave S. Hoon , Sourat Darabi , Alex Patrick Farrell , Ammar Sukari , Milan Radovich , Emil Lou , George W. Sledge Jr., Wafik S. El-Deiry , Asfar S. Azmi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3128)
DOI
10.1200/JCO.2023.41.16_suppl.3128
Abstract #
3128
Poster Bd #
326
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Therapeutic vulnerabilities among KRAS G12C mutant (mut) advanced cancers based on co-alteration (co-alt) patterns.
First Author: Maliha Nusrat
Poster
2020 ASCO Virtual Scientific Program
Clinically aggressive malignancies associated with STK11 germline mutations (STK11GCa): A comprehensive genomic profiling (CGP) study.
First Author: Ethan Sokol
Poster
2019 Gastrointestinal Cancers Symposium
Genomic alterations in appendiceal carcinoma using circulating DNA.
First Author: Walid Labib Shaib
Poster
2018 ASCO Annual Meeting
Seventeen percent of NGS 50 gene panel variants are not expressed in RNAseq.
First Author: Razelle Kurzrock